Germany · Delayed Price · Currency is EUR BioRestorative Therapies Statistics
Total Valuation
FRA:9OF has a market cap or net worth of EUR 7.94 million. The enterprise value is 4.09 million.
| Market Cap | 7.94M |
| Enterprise Value | 4.09M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 8.88M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +24.38% |
| Shares Change (QoQ) | +4.30% |
| Owned by Insiders (%) | 16.56% |
| Owned by Institutions (%) | 4.48% |
| Float | 6.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.30 |
| PB Ratio | 4.22 |
| P/TBV Ratio | 5.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.38 |
| EV / Sales | 12.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.45 |
Financial Position
The company has a current ratio of 1.37
| Current Ratio | 1.37 |
| Quick Ratio | 1.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -207.73% and return on invested capital (ROIC) is -148.19%.
| Return on Equity (ROE) | -207.73% |
| Return on Assets (ROA) | -89.73% |
| Return on Invested Capital (ROIC) | -148.19% |
| Return on Capital Employed (ROCE) | -657.55% |
| Revenue Per Employee | 29,707 |
| Profits Per Employee | -981,732 |
| Employee Count | 11 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.34% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.36 |
| Relative Strength Index (RSI) | 35.02 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, FRA:9OF had revenue of EUR 326,772 and -10.80 million in losses. Loss per share was -1.26.
| Revenue | 326,772 |
| Gross Profit | 304,998 |
| Operating Income | -12.37M |
| Pretax Income | -10.80M |
| Net Income | -10.80M |
| EBITDA | -12.19M |
| EBIT | -12.37M |
| Loss Per Share | -1.26 |
Balance Sheet
The company has 3.83 million in cash and n/a in debt, giving a net cash position of 3.83 million.
| Cash & Cash Equivalents | 3.83M |
| Total Debt | n/a |
| Net Cash | 3.83M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.88M |
| Book Value Per Share | 0.23 |
| Working Capital | 1.08M |
Cash Flow
In the last 12 months, operating cash flow was -9.14 million and capital expenditures -41,621, giving a free cash flow of -9.18 million.
| Operating Cash Flow | -9.14M |
| Capital Expenditures | -41,621 |
| Free Cash Flow | -9.18M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 93.34% |
| Operating Margin | -3,785.07% |
| Pretax Margin | -3,304.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:9OF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.38% |
| Shareholder Yield | -24.38% |
| Earnings Yield | -136.00% |
| FCF Yield | -115.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:9OF has an Altman Z-Score of -47.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -47.37 |
| Piotroski F-Score | 2 |